SCHEMBL979786

SCHEMBL979786

O=Cc1ccccc1SCCO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
THRB P10828 2/20 0.44
BLM P54132 2/20 0.44
KMT2A Q03164 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
S100A4 P26447 3/20 0.43
ALDH1A1 P00352 3/20 0.43
CDC25A P30304 3/20 0.43
CDC25B P30305 3/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 2/20 0.43
CDC25C P30307 2/20 0.43
KDM4E B2RXH2 2/20 0.43
APAF1 O14727 1/20 0.43
MAP2K7 O14733 1/20 0.43
NPC1 O15118 1/20 0.43
GMNN O75496 1/20 0.43
TDP2 O95551 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9711982 0.84 LMNA (0.48) MEN1LMNATHRBBLMKMT2A
SCHEMBL9712004 0.84 ERN1 (0.36) MEN1LMNATHRBBLMKMT2A
SCHEMBL22083867 0.81 S100A4 (0.39) MEN1LMNATHRBBLMKMT2A
SCHEMBL10364821 0.81 LMNA (0.44) MEN1LMNATHRBBLMKMT2A
SCHEMBL14279407 0.81 LMNA (0.44) MEN1LMNATHRBBLMKMT2A
SCHEMBL7760109 0.81 PTGS2 (0.47) MEN1LMNATHRBBLMKMT2A
SCHEMBL29594315 0.79 S100A4 (0.50) MEN1LMNATHRBBLMKMT2A
SCHEMBL10035839 0.79 S100A4 (0.50) MEN1LMNATHRBBLMKMT2A
SCHEMBL8595709 0.78 PTGS2 (0.51) MEN1LMNATHRBBLMKMT2A
SCHEMBL10285192 0.78 LMNA (0.41) MEN1LMNATHRBBLMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0570780-B1 Chloroethylsulphonylbenzaldehydes BASF AG (DE) 1996-03-06 EP claimed
EP-0570780-A1 Chloroethylsulphonylbenzaldehydes BASF Aktiengesellschaft (DE) 1993-11-24 EP claimed
EP-0309839-B1 PROCESS FOR THE PREPARATION OF OXYETHYL MERCAPTOBENZALDEHYDES, AND THEIR OXIDATION PRODUCTS HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-04 EP claimed
JP-6032772-A None JP disclosed
EP-2788345-B1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT CHIESI FARM SPA (IT) 2020-06-10 EP disclosed
US-9458154-B2 Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-04 US disclosed
CN-103987708-B The derivant of 4-hydroxyl-1,2,3,4-naphthane-1-base urea and the purposes in treatment of respiratory diseases thereof 奇斯药制品公司 2016-06-22 CN disclosed
US-20150057273-A1 KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-02-26 US disclosed
EP-2788345-A1 DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT Chiesi Farmaceutici S.p.A. (IT) 2014-10-15 EP disclosed
CN-103987708-A Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and uses thereof in the treatment of diseases of the respiratory tract and other diseases CHIESI FARMA SPA 2014-08-13 CN disclosed
EP-2303267-B1 POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A]PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES PFIZER LTD (GB) 2013-07-03 EP disclosed
US-20110003848-A1 Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases PFIZER LIMITED (GB) 2011-01-06 US disclosed
US-20110003848-A1 Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases PFIZER LIMITED (GB) 2011-01-06 US disclosed
US-20110003848-A1 Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases PFIZER LIMITED (GB) 2011-01-06 US disclosed
WO-2009098612-A2 POLYMORPHIC FORM OF A [1, 2, 4] TRIAZOLO [4, 3-A] PYRIDINE DERIVATIVE FOR TREATING INFLAMMATORY DISEASES PFIZER LIMITED (GB) 2009-08-13 WO disclosed
EP-0570780-B1 Chloroethylsulphonylbenzaldehydes BASF AG (DE) 1996-03-06 EP disclosed
US-5493057-A INTERMEDIATES FOR REACTIVE DYES BASF AKTIENGESELLSCHAFT (DE) 1996-02-20 US disclosed
JP-H0632772-A CHLOROETHYLSULFONYLBENZALDEHYDE BASF AG 1994-02-08 JP disclosed
EP-0570780-A1 Chloroethylsulphonylbenzaldehydes BASF Aktiengesellschaft (DE) 1993-11-24 EP disclosed
EP-0309839-A1 Process for the preparation of oxyethyl mercaptobenzaldehydes, and their oxidation products HOECHST AKTIENGESELLSCHAFT (DE) 1989-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003848-A1 Polymorphic Form Of A [1,2,4]Triazole[4,3-A] Pyridine Derivative For Treating Inflammatory Diseases CYP1B1, UBE2V1, CYP4B1 MEN1 4868/4885LMNA 3780/4885THRB 495/4885
US-20150057273-A1 KINASE INHIBITORS MAPK1, MAP3K1, MAPK4 MEN1 4726/4885LMNA 3345/4885THRB 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.